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 CRT significantly improved cognitive flexibility, memory and social function. 
 Improvement of cognitive function did not predict social function change. 






Individual-level Cognitive Remediation Therapy (CRT) has been shown to be effective for 
cognitive improvement and social function amelioration. Here, we aimed to test the efficacy of 
group-based CRT in Chinese subjects with schizophrenia. One-hundred and four inpatients were 
randomly assigned to either 40 sessions of small-group CRT therapy or therapeutic 
contact-matched Musical and Dancing Therapy (MDT). Cognitive and social functioning, as well 
as clinical symptoms, were evaluated over the course of treatment. Specifically, cognitive function 
was evaluated using a battery of cognitive measurements, clinical symptoms were evaluated using 
the Positive and Negative Syndrome Scale, and social function was evaluated using the Nurse’s 
Observation Scale for Inpatient Evaluation-30. All patients were evaluated pre- and post-treatment. 
Forty-four individuals in the CRT group and 46 in the MDT group completed all of the planned 
treatments and analyses. Cognitive functions, especially cognitive flexibility and memory, showed 
significant improvement in the CRT group over the course of the study. The MDT group also 
showed improvement in several cognitive flexibility assessments, but the degree of improvement 
was significantly greater in the CRT group. Several social-function factors exhibited a significant 
improvement in the CRT group, but not in the MDT group. Cognitive function improvement 
correlated positively with social function without predicting social function change. We conclude 
that group-based CRT is an effective and promising therapy. 





Cognitive impairment is a core feature of schizophrenia [4, 16], and deficits affecting 
processing speed, attention/vigilance, working memory, and executive function correlate with 
poor functional outcomes [3, 19, 29]. Antipsychotic agents significantly control clinical symptoms, 
especially positive symptoms. However, these agents, whether typical or atypical, produce little or 
no remediation of cognitive deficits in schizophrenia [6, 15, 31]. Because of this shortcoming, 
many non-drug therapies, most notably neurocognitive approaches such as Cognitive Remediation 
Therapy (CRT), have been developed [12, 32, 35]. CRT is a novel rehabilitation method that aims 
to teach patients “thinking” skills in order to produce improvement in cognitive processes such as 
attention, working memory, and executive function [9, 21, 33, 35]. Accumulating evidences have 
validated the efficacy of CRT [10, 22, 33, 34]. Moreover, most studies have found significant 
functional outcome improvements accompanying changes in the level of cognitive functioning [8, 
28, 37]. Prior studies confirming the efficacy of CRT [20, 24, 30] have almost entirely used 
individual-level CRT (i.e. one therapist and one participant per session). Although increasing 
evidence indicates a face-to-face approach is effective in improving cognition and social function 
in schizophrenia [26, 35], it is difficult to transfer this method to routine clinical therapy due to an 
insufficient supply of therapists. To remove this translational bottleneck, a group-based variation 
of CRT appears promising, especially in China, home to about 10 million patients with 
schizophrenia [25] who all might benefit from CRT. However, to date, evidence on the clinical 




All participants were recruited from the Beijing Huilongguan Hospital. The inclusion criteria 
were: 
 Diagnosis of schizophrenia according to the Diagnostic and Statistical Manual, 4thed. [1] 
by two attending psychiatrists;  
 Duration of illness of 2 years or more; 
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 Age 20–60 years; 
 Evidence of cognitive impairment; 
 Completion of at least 6 full years of education; 
 Clinical condition stable for at least 1 month. 
Participants were excluded for:  
 Difficulty in communicating effectively with therapists; 
 Substance abuse, as defined by the DSM-IV; 
 History of organic brain disorder or other severe organic disorder. 
All participants provided written informed consent, and the protocol was approved by 
the Beijing Huilongguan Hospital Ethics Committee. 
2.2 Procedure 
One hundred and four participants fulfilled all criteria and were randomly assigned to the 
CRT (n = 52) or the Music and Dance Therapy (MDT) groups (n = 52). A random number table 
was used to generate lots that were drawn for sealed envelopes, which assigned the participants to 
the CRT or MDT groups (see consort flow chart in Fig. 1). 
All participants were assessed before and after 10 weeks of treatment. Neurocognitive 
function, clinical symptoms, and social functioning were evaluated. Neurocognitive tests were 
carried out by two clinical psychologists, who had at least 5 years’ experience with psychometric 
testing. Clinical symptom rating (Positive and Negative Syndrome Scale, PANSS) was conducted 
by two attending psychiatrists. Social function assessment was carried out by four senior nurses, 
who had at least 5 years’ experience in psychiatric nursing. All eight raters were blind to group 
assignment.  
2.3 Measures 
The following measures were administered: 
2.3.1 Clinical assessment 
The Chinese version of the PANSS [39] was used for symptom assessment. In addition to the 
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total score, three subscales were calculated: positive, negative, and general psychopathology.  
2.3.2 Neurocognitive assessment  
(ⅰ) Stroop Neuropsychological Screening Test: This is a paper version of the ubiquitous Stroop 
test, key measurables being the reaction times for correctly naming 30 items in the following three 
categories: the color of colored circles printed in red, yellow, blue, or green; the word information 
of words printed in the same four colors; and the color information of words printed in the same 
four colors. The words were color names that were different from the color of the ink in which the 
word was printed. Two skilled clinical psychologists used a professional stopwatch to measure 
the reaction times. 
(ⅱ) Category Fluency Test (CFT): Participants were asked to provide as many different names of 
fruits or animals as possible in one minute, the score being the number of such names provided. 
(ⅲ) Verbal Fluency Test (VFT): Participants were asked to provide as many different Chinese 
common words as possible in one minute consisting of two to four Chinese characters beginning 
with a cue character provided by the test giver. For example, if the latter were “工”, which means 
“working,” participants could use it to make a word such as “工人,” or “worker.” In each test, five 
cue characters were given sequentially and the score was the total number of valid words 
generated. 
(ⅳ) Trail Making Test-A: The key measurable was the time required to draw a trail in numerical 
order through a set of numbers running from 1 to 25, where the numbers were randomly placed. 
Time required to perform Trail Making Test-A was also recorded using a professional 
stopwatch. 
(ⅴ) Logical Memory Test: Wechsler Memory Scale-Revised: Immediate-recall total score and 
delayed-recall total score. 
(ⅵ) Benton Visual Retention Test (BVRT) [7], Form C: Participants were asked to reproduce 10 
simple geometric designs in turn from memory. The key measurables were numbers of right and 
wrong responses.  
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(ⅶ) Digit Span (Wechsler Adult Intelligence Scale-Revised): Administered according to the 
standard WAIS-R instructions. The key measurable was the age-scaled score. 
2.3.3 Social functioning assessment 
A Chinese version [18] of the Nurse’s Observation Scale for Inpatient Evaluation 
(NOSIE)-30 [14] was used to evaluate participant behavior and social functioning. The 
measurables comprised a total score, a positive-factor score, and a negative-factor score. 
2.4 Therapy 
The CRT protocol was based on a Chinese version of the CRT manual, originally derived 
from an English version of Frontal/Executive Function Program (Revised) [5, 34]. This therapy 
consists of three modules: 1) the “Cognitive Shift Module,” addressing flexibility in thinking and 
information-set maintenance; 2) the “Working Memory Module”, addressing working memory 
capacity, which has participants work with two to five information sets at a time; and 3) the 
“Planning Module,” which training the ability for self-ordered, goal-oriented, set/schema 
formation, manipulation, and planning [23, 38]. 
Participants received 40 hourly sessions at an average rate of 4 per week. Four therapists, 
after standard CRT therapy training, helped the participants finish the CRT tasks, which were 
mainly done with pencil and paper. Each therapist conducted testing of 3–4 participants 
simultaneously with the details of the process varying with individual performance in treatment. 
To minimize errors, the therapist also discussed information-processing strategies and how to 
regulate, organize, and monitor behavior. As described in other reports [12, 33], many therapeutic 
techniques such as errorless learning, verbal indicating, and scaffolding were used to ensure 
therapeutic effects. 
Patients randomized into the control group, MDT, had the same number of therapeutic 
sessions as the CRT group. MDT therapy had two different activities: playing music (learning to 
play a fairly easy instrument, namely the xylophone) and dancing (learning to dance). 
2.5 Data Analyses 
Primarily, a series of intent-to-treat analyses were used to examine all outcome variables. 
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Repeated-measures ANOVA was employed to find main effects of CRT vs. MDT on all outcome 
variables. To better understand the clinical significance of outcome improvements, effect size (ES) 
for a given variable was calculated as the difference after treatment between CRT and MDT 
groups divided by the pooled standard deviation. 
Finally, a series of correlation tests were used to investigate the correlations among the 
pre-post changes in cognitive domains, clinical symptoms, and social functions. If evidence of a 
correlation between two outcomes was found, such as cognitive improvement and social 
functioning changes, a stepwise regression model was calculated in which initial function scores 
were entered first, to test the hypothesis that some cognitive changes may be predictors of social 
function improvement and clinical symptom amelioration.  
3. Results 
3.1 Demographic characteristics 
During treatment, eight participants in the CRT group (1 discharged, 2 clinically aggravated, 
and 5 refusing to continue after 2–10 sessions of treatment) and six participants in the MDT group 
(2 discharged, 1 clinically aggravated, and 3 refusing to continue after 2–8 sessions of therapy) 
dropped out. Ultimately, 44 participants in the CRT group and 46 participants in the MDT group 
completed the study and provided adequate data for analysis. At study entry, there was no 
significant intergroup difference in any demographic feature, cognitive function, or clinical 
symptom (Table 1).  
3.2 Cognitive Function 
Within-group paired t-testing showed that six of ten cognitive variables improved 
significantly after treatment in the CRT group, while only four improved in the MDT group. After 
treatment, performance on the Trail Making–A, VFT, Stroop-word color, BVRT-correct, and 
BVRT-wrong tests improved significantly in the CRT group compared to the MDT group, as 
assessed by repeated-measures ANOVA (Table 2). 
3.3 Symptomatology 
The PANSS total scores, PANSS negative scale, and PANSS general psychopathology scale 
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showed significant improvements (within-group paired t-test) after treatment in both the CRT and 
MDT groups. There was no group difference in the total score or in any of the subscales of the 
PANSS after treatment (Table 3). 
3.4 Social functioning 
The total and general negative NOSIE scores within the CRT group showed significant 
improvements after treatment. A significant group difference in total NOSIE scores, with general 
negative and general positive subscale scores exhibiting significant group trends, was also found. 
There was no significant change in the total score or in any subscale of NOSIE in the MDT group 
after treatment (Table 3).  
3.5 Correlations among improvements in cognitive, clinical symptom, and social functioning 
Correlation testing revealed several significant positive correlations: cognitive functioning 
improvement and clinical symptom alleviation, i.e., VFT vs. general psychopathology scale of 
PANSS (r = 0.48, p < 0.01); cognitive functioning improvement and social functioning 
enhancement, i.e., VFT vs. total score of NOSIE (r = 0.37, p < 0.05); and clinical symptom 
alleviation and social functioning enhancement, i.e., general psychopathology scale of PANSS vs. 
general negative scale of NOSIE (r = 0.39, p < 0.05). Stepwise regression modeling revealed that 
neither cognitive improvement nor clinical change was involved in the social functioning model. 
4. Discussion 
As expected, the present study showed there was significant improvement in many cognitive 
performance measures after CRT treatment. Although performance on several cognitive tests also 
improved in the MDT group, the benefits conveyed by CRT were considerably greater in these 
instances. MDT was implemented here as an alternative non-pharmacological therapy to control 
for Hawthorne effects. This therapy is commonly prescribed for persons with mental disorders in 
China. Indeed, cognitive test performance did improve with MDT, suggesting that therapeutic 
contact and amusement activity may have some benefit for cognitive function. However, other 
cognitive variables such as Trail-Making A and BVRT changed little with MDT. This indicates 
that these non-specific factors have a relatively small effect on neurocognition in schizophrenia. 
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Therefore, the distinct advantages of CRT in improving performance on a range of cognitive tests 
revealed here cannot be attributed to practice or to intensive therapeutic input, but rather are 
mainly attributable to specific effects of CRT. These findings replicate the main results of prior 
studies of CRT efficacy [10, 12, 17, 35]. Our results further suggest that small-group-based CRT 
has effects comparable to face-to-face, individualized CRT in improving cognitive function even 
for severe disability and long disease duration inpatients with schizophrenia. These results thus 
demonstrated that group-based CRT is an effective alternative to one-on-one CRT with greater 
scope and efficiency (one therapist can treat 3–4 participants simultaneously). This is especially 
relevant for psychiatric practices in China given the vast number of patients in need of such 
treatment. 
CRT treatment was associated with significant improvement in the PANSS total scores and 
two PANSS subscales. However, a similar pattern was observed in the MDT group, and no 
significant difference was found between the two groups. Therefore, CRT’s impact on clinical 
symptoms was small and non-specific. This is consistent with prior studies concluding that CRT 
has little impact on clinical symptoms as measured by PANSS [2]. After CRT treatment, the total 
and general negative NOSIE scales were significantly improved. This finding is also 
well-precedented [10, 23] and indicates that CRT not only has therapeutic effects on cognitive 
function, but also on social function. Many studies have established that cognitive function 
correlates with social function in schizophrenia [11, 27]. In present study, a significant positive 
correlation between cognitive flexibility (VFT test) and social function was found. However, this 
cognitive improvement did not predict social function change in further regression analysis; this 
result is in closer accordance with prior research [27]. These contradictory results of correlation 
and regression analysis may reflect the complex relationship between cognitive and social 
function [28]. 
In summary, given that we adopted a less focused and intensive therapeutic 
mode—small-group therapy versus one-on-one—and recruited participants with severe disability, 
relatively advanced ages, and comparatively longer disease durations, these results were especially 
encouraging. Combined with previous research, the present results indicate that CRT is an 
effective and promising therapy for improving cognitive function and social outcomes for 
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participants with schizophrenia, even those with severe disability.  
Despite these promising findings, the present study has several limitations. First, because the 
durability of cognitive and social-function benefits obtained from neurocognitive treatment is 
considered particularly important, many earlier studies have shown that the effect of these 
therapies can last 6 to 24 months [10, 13, 23], the lack of follow-up data in the present study is 
therefore an obvious limitation. Future studies should evaluate the durability of effects. Second, 
earlier research suggests that CRT could improve the self-esteem of participants with 
schizophrenia at post-treatment [36] and the present study lacks self-esteem data. Investigations of 
participants’ subjective experience should be included in future studies. 
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Table 1. Demographic and clinical characteristics of participants at entry to the study 
Characteristics 
CRT group  
(n = 52) 
MDT group 
(n = 52) 
Sex (male: female) 27:17 27:19 
Mean age (SD), year 46.77 (7.18) 46.09 (5.52) 
Mean education level (SD), year 9.70 (1.85) 10.13 (2.42) 
Mean illness duration (SD), year 23.95 (8.18) 21.51 (6.50) 
Years in hospital (SD), year 9.95 (7.52) 9.53 (6.61) 
WAIS-R (intelligence quotient, IQ) 80.16 (14.04) 79.57 (13.86) 
Mean (SD) PANSS score   
Positive Scale 14.31 (4.66) 12.74 (4.15) 
Negative Scale 20.24 (4.67 ) 19.43 (4.93) 
Total Scale 67.26 (11.32) 65.57 (11.34) 
Neuroleptic medication use   
Atypical rate  52.23% 52.32% 
Atypical dosea (mg) 221.23 (129.34) 234.42 (189.31) 
Typical dosea (mg) 346.31 (173.23) 331.32 (178.25) 
Mean dosea 280.32 (162.15) 275.15 (140.41) 
CRT, Cognitive Remediation Therapy; MDT, Music and Dancing Therapy; WAIS-R, Wechsler Adult Intelligence 
Scale—revised. 






Table 2. Repeated measures ANOVA for mean (S.D.) scores on Cognitive function by group (CRT and MDT) for 
baseline and post-treatment. 
Outcome Measure     
 
CRT Group (n = 44) MDT Group (n = 46) Group by Time 
Interaction 
Effect  
Size    Baseline  Post-treatment Baseline Post-treatment 
Mean SD Mean SD Mean SD Mean SD F P d     
Cognitive Flexibility 
Trail Making–A 82.95 35.12 61.81a 28.87 85.22 41.99 80.10 39.12 9.530 0.003 0.651 
CFT 18.59 6.30 19.39 5.79 17.52 5.91 17.54 5.66 0.362 0.549 0.127 
VFT 20.09 7.51 21.05 8.10 19.85 9.21 16.28a 8.07 9.186 0.003 0.639 
Stroop-color circle 31.43 19.74 23.66a 9.46 33.20 15.31 28.04a 10.52 0.706 0.403 0.176 
Stroop-colored word 33.73 22.35 22.80a 11.36 35.30 16.20 30.85a 14.54 2.810 0.097 0.366 
Stroop-word color 52.82 20.12 46.52a 14.17 50.65 16.78 55.91 17.90 12.444 0.001 0.742 
Memory            
Digit Span-total 11.09 2.22 10.93 2.25 10.11 1.78 10.09 1.99 0.130 0.720 -0.076
BVRT-correct 4.05 1.88 6.26a 1.82 4.61 2.01 5.07 1.70 20.924 0.000 1.006 
BVRT-wrong 10.13 4.80 5.62a 3.18 9.27 4.29 8.30a 3.95 17.580 0.000 0.912 
Logical Memory 4.33 1.49 4.60 2.04 3.63 2.11 4.09 1.88 0.167 0.684 -0.089
CRT, Cognitive Remediation Therapy; MDT, Musical and Dancing Therapy; CFT, Category fluency test; VFT, 
Verbal fluency test; BVRT, Benton Visual Retention Test. 





Table 3. Repeated measures ANOVA for mean (S.D.) scores on Clinical symptom (PANSS) and social functions by 
group (CRT and MDT) for baseline and post-treatment. 
Outcome Measure     
 
CRT Group (n = 44) MDT Group (n = 46) Group by Time 
Interaction 
Effect  
Size    Baseline  Post-treatment  Baseline Post-treatment 
Mean SD Mean SD Mean SD Mean SD F P d     
Clinical symptoms 
PANSS Total  67.26 11.32 59.76a 10.17 65.57 11.34 58.14a 10.50 0.001 0.977 0.000 
PANSS Positive 14.31 4.66 12.93 3.31 12.74 4.15 12.00 4.19 0.575 0.451 -0.175 
PANSS Negative 20.24 4.67 17.29a 4.44 19.43 4.93 16.49a 4.01 0.000 0.992 0.002 
PANSS general  
psychopathology 29.76 4.99 27.12
a 4.15 29.06 5.91 25.77a 3.83 0.300 0.586 0.124 
 Functions            
NOSIE Total 155.51 30.41 161.78a 20.20 169.51 33.70 163.95 27.42 4.208 0.044 0.465 
NOSIE General 
Negative 24.81 16.18 22.32
a 10.92 20.78 16.61 23.80 14.96 3.780 0.056 0.440 
NOSIE General 
Positive 52.32 19.42 56.11 12.59 62.29 20.26 59.76 15.23 
3.250 0.075 0.409 
CRT, Cognitive Remediation Therapy; MDT, Musical and Dancing Therapy; PANSS, positive and negative score; 
NOSIE, Nurse’s Observation Scale for Inpatient Evaluation. 
a within group paired–t test, p<0.05. 
 
